Research
Awards Grant
(IMPAACT) Subcontract BRS-IPHRM-S-08-00056, Equipment
A Multicenter, Open-Label, Noncomparative Study for the International Maternal, Pediatric, Adolescent AIDS Clinical Trials Group to Evaluate the Safety, Pharmacokinetics, and Antiretroviral Activity of MK-0518 in HIV-1 Infected Children (Study)
A Prospective, Phase III, Open-Label Study of Boceprevir, Pegylated-Interforn Alfa 2b and Ribavirin in HCV/HIV Coinfected Subjects: Boceprevir, Interferon, Ribavirin to Treat HCV/HIV/Coinfected Subjects (BIRTH)
A5210.04-University of Alabama at Birmingham - VSL 54
A5280 "A Prospective, Randomized, Double-Blind Phase II Trial of High-Dose Vitamin D and Calcium for Bone Health in HIV-Infected Individuals Initiating Highly Active Antiretroviral Therapy (HAART)"
ACTG Protocol A5269 The Activity of Nitazoxanide in Addition to Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Treatment-Naïve Genotype 1 Subjects with HIV Coinfection
Adult Clinical Trials Group Protocol #A5272 Supplemental Funds
Adult Clinical Trials Group Protocol #A5277 Supplemental Funds
Adult Clinical Trials Group Protocol #A5280 Supplemental Funds
Adult Clinical Trials Group Protocol #A5303 Supplemental Funds
Adult Clinical Trials Group Protocol#A5257 Supplemental Funds
BRS-ACURE-S-12-000054-002502 ACTG 5801
International Maternal Pediatric Adolescent AIDS Clinical Trials Group ("IMPAACT")
International Maternal Pediatric Adolescent AIDS Clinical Trials Group ("IMPAACT")
International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT)
International Maternal Pediatric Adolescent AIDS Clinical Trials Group Leadership (ARRA Administrative Supplement)
Slide Scoring in the Investigation between the Vaginal Microbiota and Uterine Fibroids
UAB ACTG Pharmacology Support Laboratory
UAB IMPAACT Pharmacology Support Laboratory
Virology Specialty Laboratory
